Natural History of Nonhuman Primates After Oral Exposure to Ebola Virus Variant Makona

J Infect Dis. 2023 Nov 13;228(Suppl 7):S571-S581. doi: 10.1093/infdis/jiad225.

Abstract

Background: The primary route of infection by Ebola virus (EBOV) is through contact of mucosal surfaces. Few studies have explored infection of nonhuman primates (NHPs) via the oral mucosa, which is a probable portal of natural infection in humans.

Methods: To further characterize the pathogenesis of EBOV infection via the oral exposure route, we challenged cohorts of cynomolgus monkeys with low doses of EBOV variant Makona.

Results: Infection with 100 or 50 PFU of EBOV Makona via the oral route resulted in 50% and 83% lethality, respectively. Animals that progressed to fatal disease exhibited lymphopenia, marked coagulopathy, high viral loads, and increased levels of serum markers of inflammation and hepatic/renal injury. Survival in these cohorts was associated with milder fluctuations in leukocyte populations, lack of coagulopathy, and reduced or absent serum markers of inflammation and/or hepatic/renal function. Surprisingly, 2 surviving animals from the 100- and 50-PFU cohorts developed transient low-level viremia in the absence of other clinical signs of disease. Conversely, all animals in the 10 PFU cohort remained disease free and survived to the study end point.

Conclusions: Our observations highlight the susceptibility of NHPs, and by extension, likely humans, to relatively low doses of EBOV via the oral route.

Keywords: EVD; Ebola virus; Filoviridae; Makona; filovirus; hemorrhagic fever virus; mucosal exposure; nonhuman primate; oral exposure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Biomarkers
  • Disease Models, Animal
  • Ebolavirus*
  • Hemorrhagic Fever, Ebola*
  • Humans
  • Macaca fascicularis
  • Viremia

Substances

  • Biomarkers